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ABSTRACT We have investigated the influence of genetic
instability [replication error (RER) phenotype] on APC (ad-
enomatous polyposis coli), a gene thought to initiate colorectal
tumorigenesis. The prevalence ofAPC mutations was similar
in RER and non-RER tumors, indicating that both tumor
types share this step in neoplastic transformation. However,
in a total of 101 sequenced mutations, we noted a substantial
excess ofAPC frameshift mutations in the RER cases (70% in
RER tumors versus 47% in non-RER tumors, P < 0.04). These
frameshifts were characteristic of mutations arising in cells
deficient in DNA mismatch repair, with a predilection for
mononucleotide repeats in the RER tumors (P < 0.0002),
particularly (A). tracts (P < -0.00007). These findings suggest
that the genetic instability that is reflected by the RER
phenotype precedes, and is responsible for, APC mutation in
RER large bowel tumors and have important implications for
understanding the very earliest stages of neoplasia in patients
with tumors deficient in mismatch repair.
Instability at simple repetitive DNA sequences has been
observed in a subset of sporadic colorectal cancers (1, 2) and
in essentially all tumors from patients with hereditary non-
polyposis colorectal cancer (HNPCC) (3-5). Deficiency in
binding and repair ofDNA mismatches has been demonstrated
in tumor cell lines exhibiting such instability (6-10), and
studies show an increased spontaneous mutation rate in se-
lectable genes (8, 11-13). In most HNPCC tumors and in many
of the sporadic cases, the underlying basis of this mutator or
RER (replication error) phenotype is mutational inactivation
of a human mismatch repair gene, five of which have so far
been described (10, 14-18). With the exception of GTBP/pl60
(19), germ-line mutations have been identified in each of these
genes in HNPCC families (5, 15-18, 20, 21). However, mis-
match repair gene mutations can only be detected in about half
of sporadic colorectal tumors that exhibit an RER phenotype
(19, 22, 23), suggesting that other genes may also contribute to
genetic instability in the nonfamilial cases.
A substantial proportion of RER cell lines have inactivating
mutations in the type (3 transforming growth factor (TGF-,B)
receptor 11 (24, 25), but there are little other data on the role of
defective mismatch repair (MMR) in the generation of mutations
in genes that are specifically implicated in tumorigenesis. In this
study, we sought to investigate the influence of genetic instability
on the frequency and the spectrum of APC (adenomatous
polyposis coli) gene mutations in colorectal tumors. Mutational
inactivation of the APC gene appears to initiate colorectal
tumorigenesis, not only in mice and humans with germ-line
alterations ofAPC, but also in patient populations with sporadic
colorectal neoplasia. Hence it is of considerable interest to
determine the nature of processes that may be responsible for the
development of such mutations. Here, we show a striking rela-
tionship in colorectal tumors between the APC mutational spec-
trum and the presence of genetic instability manifest as the RER
phenotype. Our findings provide insight into mechanisms by
which defective DNA mismatch repair leads to the development
of cancer in humans and demonstrate that such mismatch repair
deficiency has important influence from the very earliest stages
of tumorigenesis in the colorectal epithelium.
MATERIALS AND METHODS
Collection of Clinical Material and Template Preparation.
All patients had undergone resection of histologically verified
colorectal adenomas or carcinomas. Familial adenomatous
polyposis cases were excluded. The following criteria had to be
fulfilled for assignment as an HNPCC case: three first-degree
relatives affected by pathologically confirmed colorectal can-
cer, one affected case arising under 50 years of age, one
affected case to be the first-degree relative of the other two,
and two or more affected generations (26).
Fresh tumor samples were from patients with colorectal
neoplasms undergoing surgery in Edinburgh Royal Infirmary
or The Johns Hopkins Hospital. Cell lines were derived from
colorectal cancers as described (27) or from American Type
Culture Collection and were passaged either in nude mice or
in vitro. DNA and RNA were purified from peripheral blood
leukocytes, fresh tumor tissue, adjacent normal colonic mu-
cosa, cell lines, and xenografts by standard protocols. For RER
and APC mutation analysis of primary tumors, constitutional
RNA and DNA were compared with that prepared from fresh
tumor tissue taken from cryostat sections (28) or immediately
adjacent to regions identified on hematoxylin/eosin staining as
containing >60% neoplastic tissue.
RER Analysis. RER analysis was performed by using four
or more microsatellite PCR markers from the following set:
D2S123, D2S119, D3S1293, D8S282, D13S160, D18S58,
TGF-13 receptor II, BAT26, BAT40. Primer sequences and
PCR conditions have been reported elsewhere (25, 29, 30). To
be categorized -as RER, tumors were required to demonstrate
variations compared with control tissue in at least half of the
markers tested. Following electrophoresis on denaturing gels
containing formamide, alleles were visualized either by silver-
staining (31), autoradiography of radiolabeled products, or by
analysis of fluorescent labeled products using a Pharmacia
Abbreviations: RER, replication error; MMR, mismatch repair; IVSP,
in vitro synthesized protein; HNPCC, hereditary nonpolyposis colo-
rectal cancer; TGF-,B, type 13 transforming growth factor.
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automated laser fluorescence (ALF) automated sequencer
and the manufacturer's software.
APC Mutation Screening Strategy. Screening forAPC gene
mutations was performed by an in vitro synthesized protein assay
(IVSP) which allows detection of truncated surrogate APC
protein products as described (32-34). In brief, IVSP involved
PCR amplification of 100-200 ng ofDNAorcDNAby usingPCR
primers to introduce a 17-bp consensus T7 promoter sequence
and a mammalian translation initiation sequence in frame with
unique APC sequence. PCR primer-pair sequences and PCR
conditions are available on request and are similar to those
previously described (32). For exons 1-14 (segment 1), cDNAwas
produced by reverse transcription of tumor RNA followed by
PCR amplification (32, 33). Exon 15 was amplified in four
overlapping fragments (segments 2-5) from genomic DNA tem-
plates. Resultant PCR products were used in a coupled transcrip-
tion-translation reaction (Promega) incorporating 5-10 mCi (1
Ci = 37 GBq) of 35S-labeled methionine according to the
manufacturers instructions. Labeled protein products from the
reaction were heat denatured and analyzed by 8%, 10%, and 12%
SDS/PAGE gels. Gels were washed in fixative and autoradiog-
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raphy was performed at room temperature overnight (32). All
samples showing truncated protein products were independently
reamplified and a further IVSP analysis was performed for
confirmation.
In 28 cell lines, truncating mutations were identified by using
Western blots instead of IVSP assays, performed with mono-
clonal antibody FE9, as described (35). In 20 of these lines, the
presence or absence of truncated APC had been reported
previously (35).
DNA or cDNA from tumors with reproducible truncations
were subjected to independent amplification. PCR fragments
were purified and sequenced by using Sequenase 2 (United
States Biochemical) with 35S-labeled dATP or SequiTherm
polymerase (Epicentre Technologies, Madison, WI) with 32p_
labeled primers. Termination of the reactions was followed by
electrophoresis in 6% acrylamide under denaturing condi-
tions. Dried sequencing gels were exposed to XAR (Kodak)
film overnight.
RESULTS
Prevalence of TruncatingAPC Mutations in RER Tumors.
To allow meaningful assessment of the prevalence of APC
mutations in RER tumors, we analyzed a sufficient number of
primary tumors and cell lines to identify a relatively large
number of RER cases. In all, 52 RER tumors were identified
for mutation analysis of theAPC gene by combining 20 tumors
from a new prospective cohort with 32 tumors identified in our
previous studies of genetic instability (3, 5, 6, 22, 25). Nineteen
of these 52 tumors were derived from patients who were
members of different HNPCC kindreds, and the remainder were
not associated with any known family history of colorectal cancer.
Sixty-three non-RER tumors were selected randomly from the
412 sporadic tumors analyzed to acquire the 52 RER cases. The
fraction ofRER tumors among the total sporadic cases examined
(15.8%) was similar to that reported in previous studies (1-3, 36,
37). Examples of the microsatellite assays employed for deter-
mination of RER status are shown in Fig. 1.
Screening for truncatingAPC mutations was performed on
the 115 tumors in the combined RER groups by using either
IVSP assays (32-34) or Western blots (35) as described. Both
assays are highly reliable indicators ofAPC mutation status, as
virtually all pathogenic APC mutations result in truncated
proteins (38). Examples of positive IVSP assays are shown in
Fig. 2. The prevalence of truncatedAPC gene product detect-
able by our assays was somewhat lower in the RER tumors (29
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FIG. 1. Microsatellite instability. Representative PCR amplified
products from the Pharmacia ALF automated sequencer using fluo-
rescent-labeled primers for D13S160 in three separate tumors with
normal DNA from the same patient for comparison. Allele sizes are
given along the x axis. Tumor marker patterns are represented by
broken lines and normal, constitutional PCR products from the same
patient by continuous lines. Each of these tumors exhibits microsat-
ellite instability and shows novel, tumor-specific alleles (indicated by
*). Contractions of one allele are shown in tumors from patients A and
B, while in the tumor from patient C there has been both expansion
and contraction at the D13S160 locus.
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FIG. 2. APC mutation analysis. IVSP data forAPC gene segment
encompassing codons 1099-1693 are shown inA for non-RER tumors
T28 and T15 and for RER tumors C039 and C086 with a control
reaction using lymphocyte DNA from a healthy donor as template.
Arrows show truncated protein products, and the sequence alterations
responsible for each of these are listed in Tables 1 and 2. Example
sequence analysis (B) of purified PCR products amplified from tumors
T15 and C039 with constitutional genomic DNA from the same
patient as control in each case.
C039b N
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of 52; 56%) compared with non-RER tumors (47 of 63; 75%),
but this difference was not statistically significant (0.10 > P>
0.05). There was no difference in theAPC mutation prevalence
between primary RER tumors (19 of 34; 56%) and RER cell
lines (10 of 18; 56%). In addition, APC mutation prevalence
was similar whether the RER tumor was derived from HNPCC
patients (10 of 19; 53%) or from patients without a strong
family history of colon or rectal cancer (19 of 33; 58%).
Comparison of APC Mutations in RER and non-RER
Tumors. For comparison of the APC mutation spectrum in
RER tumors with that in non-RER cases,APC sequence data
were collated from two sources: from sequence analysis of
tumors shown to haveAPC truncations in the IVSP or Western
blot assays described above, and from sequence data obtained
from tumors studied previously in our laboratories (39-42),
for which we determined the RER status as part of the present
study. These two sources provided a total of 101 APC muta-
tions, 37 from RER tumors and 64 from non-RER lesions,
sufficient to determine whether the RER phenotype had any
influence on the APC mutational spectrum in colorectal
tumors. The sequence alterations and target sequences for
each of these 101 mutations are shown in Table 1 for RER
tumors and in Table 2 for non-RER tumors. Mutations that
have previously been reported are indicated in each table.
Of the whole set of 101 APC mutations, 51 were newly
characterized from tumors shown to have an APC truncation
in the assays described above. Sequencing was performed on
PCR products amplified from genomic DNA or cDNA tem-
plates, and representative results are shown in Fig. 2, along
with corresponding protein truncation data. In all, there were
27 mutations from 22 RER tumors and 24 mutations from 23
non-RER tumors. All 29 RER tumors with truncations were
analyzed in detail but precise determination of the underlying
mutation was not possible in 7 cases because of insufficient
high quality nucleic acids or because the mutation could not be
identified despite extensive sequencing. We selected 25 non-
RER cases with APC truncations, largely on the basis of
nucleic acid availability, and determined the sequence alter-
ation responsible for the truncation noted on IVSP assay or on
Western blot in all but 2 of these cases. These APC sequence
data from the two RER tumor groups were combined with a
total of 50 mutations identified in 36 tumors that have previ-
ously been reported from our laboratories (39-42). The RER
status of these tumors had not been determined and so these
were systematically assessed using microsatellite markers as
described in Materials and Methods and on exactly the same
basis as the assignment of the RER status to the tumor set
assessed in the protein truncation assays. Ten APC mutations
Table 1. APC mutations and target sequence in RER tumors
Family APC
Tumor ID history change, nt Codon Target sequence
Frameshift mutations
Mutation target in mononucleotide repeat
Ca6# S 1 bp del 758 AACaAAAAGCC
Cal8*# S 2 bp del 773 GAAACttTTGAC
Ca8# S 1 bp del 801 TATGtTTTTGAC
Cx7* H 1 bp ins 847 TCTG(±4lAAAAAGAT
K10 H 1 bp del 907 TCTgGGTCT
C086* H 1 bp ins 941 TCGGfAjAAAATTCA
C039* NK 1 bp del 975 GGTaAAAGAGGT
Ca18* S 1 bp ins 1307 GCAGaAAATA
T19 NK 2 bp del 1354 GAAttTTCTT
S175 S 1 bp del 1429 GGACaAACC
C081, TSh4O S'S 1 bp del 1437 AGTaAAACACC
K40 H 1 bp ins 1454 CCT(AIAAAAATAAA
CalO*# S 1 bp del 1454 CCraAAAATAAA
18*, CalO*# S'S 2 bp del 1461 GCTGaaAGAG
22 H 1 bp ins 1554 GCAGf&AAAAAACTAT
18* S 1 bp del 1554 GCAGaAAAAACT7AT
C088 S 1 bp del 1818 TTTGaAAAACG
Mutation target in dinucleotide repeat
C039*, C086* NK,H 2 bp del 1462 Aa~gAGAGAGAGTGG
Mutation target in nonrepeat sequence
K39 H 2 bp del 799 GATtaTGTT
Ca2O# S 1 bp del 1405 TCCgTTCAG
Colo* NK 1 bp ins 1431 CAAACCf4&ATGCC
T8 S 1 bp ins 1500 GGA.AITTTTCIT
Cxlo H 1 bp ins 1935 TTTCCCC(fjAGTCA
Transition mutations
Cal2*# S C- T 232 CpG
Cal#, Cal2*# S'S C -~T 564 CpG
T27 H C-*T 876 CpG
Colo* NK C-*T 1114 CpG
T533 H C- T 1338 CGp
Mxl4 S C- T 1367 CpA
C020 S C-*T 1444 CpA
Kl, Cx7* H,H C- T 1450 CpG
Transversion mutations
C030 S G --+ T 1499 GpG
APC mutation data for RER tumors including sequence alteration and mutational target. Insertion (ins) mutations are
underlined and the inserted sequence is shown in uppercase lettering in parentheses. The sequence removed by deletion (del)
mutations is underlined. Tumors marked with * indicate those cases in which more than one mutation was identified. Mutations
identified by our laboratories that have previously been reported in the literature (39-41) are indicated by #. A family history
indicated by H or S denotes HNPCC or sporadic cases, respectively, as defined in the text, and NK was entered where the family
history was incomplete.
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proved to be from RER tumors and the remaining 40 from
non-RER cases.
A comparison of the nature and location of the whole set of
101 APC mutations in RER and non-RER tumors is presented
in Table 3. There were a number of striking differences in the
mutation spectrum between the two RER tumor categories. A
substantial excess of frameshift mutations in the RER tumors
was observed: 70% of the mutations in RER tumors were
insertions or deletions, while only 47% of the mutations in the
non-RER tumors were of this type (P < 0.04, X = 4.3; Table
3). The excess of frameshift mutations was observed in both
HNPCC (8 of 12; 75%) and sporadic tumors (14 of 20; 70%)
exhibiting the RER phenotype.
Most of the insertions or deletions in the RER tumors were
within simple repeated sequences (Table 1 and 3). Twenty-one of
26 (81%) frameshift mutations in RER tumors occurred within
such microsatellites, compared with only 11 of 30 (37%) in
non-RER tumors (P < 0.003, X = 9.33). Mutations within (A)n
tracts were especially prominent in the RER tumors, accounting
for 49% ofallAPC mutations detected in RER tumors, while only
Table 2. APC mutations and target sequence in non-RER tumors
Tumor ID APC change, nt Codon Target sequence
Frameshift mutations
Mutation target in mononucleotide repeat
Cal6#
S82#
UC5*#
Adl*#, UC4*#, Ad4*#
H-Ad4
H65
Cal4*#
Mutation target in dinucleotide repeat
UCs*#
S80#
Ad3#
Mutation target in nonrepeat sequence
Ad2#
H-Ad9
H-Ad3
H-Adl
T10
Ca4*#
T775
Ti
AM13
AdlO#
R5#
S79#
Ad9#
H-Ad2
UC9#
T34#
UC11#
Cal9#
Ad4*#
Ca2#
T27#
Ad4*#
T9
S78, Ca4*#, Adl*#
T12
T201, T607
Ad7#, T15, AM31
H-Adl3
T24
Adl2#, UC8#, T7,
Ca22*#, TShl6,
Cal4*#, UC4*#
5
1 bp del
1 bp del
1 bp del
1 bp ins
2 bp del
2 bp del
2 bp del
1 bp del
2 bp del
4 bp ins
869
1490
1534
1554
1309
1420
1461
1464
1328
1465
1 bp del 403
1 bp del 1317
1 bp del 1407
1 bp del 1416
1 bp del 1416
1 bp del 1443
1 bp del 1489
1 bp ins 1022
1 bp ins 1318
1 bp ins 1373
1 bp ins 1376
1 bp ins 1578
1 bp ins 1941
2 bp del 1489
4 bp del 1156
5 bp ins 289
8 bp del 1489
17 bp del 1354-9
Transition mutations
G A (splice) 141-177
A G (splice) 278-311
C T 332
C T 405
C T 805
C T 876
C T 1114
C T 1338
C-T 1367
C > T 1378
C T 1406
C T 1450
A-T
A -+T
C --A
C-*A
C-A
C -*A
G-T
G -+T
G --T
G ->T
Transversion mutations
GaAAAT
TTATTACAtTTTGCCA
AATgGGAAT
GCAG(A)AAAAAACTAT
GaaAAG
AGccCCAGT
GCTGaaAAGAGA
AAGAGAGaGAGTGG
TGTcaCAGCA
GAGAGAGAG(AGAG)TGG
CGTgAAATC
GCTgAAG
CAGAGtGAA
AGTgGCATT
AGTGGcATTATA
CCTCCtCAA
TTAtTACATTT
CTAG(fTATA
GAA(A)GAT
GTCCA(C)CCTGA
CACT(AIATGTT
GAAGAATI)TGTATT
GACATA(A)CCAGAC
TTATtaCATTT
GAAGAAGaagaGAG
GCC(CAGCC)AGT
TTATtacattttGCCA
TGAattttcttcapa2cpaAATCT
GpG
ApT
CpG
CpG
CpG
CpG
CpG
CpA
CpA
CpA
CpA
CpG
CpG
ApA
ApA
TpC
CpA
CpA
CpA
GpA
GpG
GpA
GpA
1469
670
1359
906
1281
1344
1346
1020
1312
1353
1408
Ca2l#
T32
Ca22*#
Adll#
S83#
Ca25#
S77#
S84#-
T28
Adl5#
APC mutation data for non-RER tumors with deleted (del) or inserted (ins) sequence shown in the same format as in Table 1.
Tumors with more than one sequenced mutation are identified by an * and mutations previously reported from our laboratories
(35, 39-41) by #. All but one (T10) of these non-RER tumors were from patients with no family history suggestive of HNPCC.
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11% of the mutations in non-RER cases were of this type (P <
0.00007, X2 = 15.93). The complete lack of deletion or insertion
of more than 2 bp in RER tumors was also notable.
Point mutations were accordingly less frequent in the RER
cases (30%) than in the non-RER cases (53%). In contrast to
the frameshifts noted above, the targets for point mutation
were largely similar in the two RER groups. Although there
was a tendency for transitions rather than transversions in the
RER tumors, this difference was not statistically significant
(Table 3). All point mutations identified in RER tumors
occurred at C:G base pairs and all but one resulted in C -- T
changes (Tablel and 3). In both the RER and non-RER cases,
CpG dinucleotides seemed to be the favored mutation sites,
being affected in 8 of 11 (73%) and 15 of 34 (44%) of the point
mutations in RER and non-RER tumors, respectively (P = not
significant) (Tables 1 and 2).
DISCUSSION
Two major conclusions can be drawn from this study. First, APC
mutations occur in the majority ofRER and ofnon-RER tumors,
suggesting that both tumor types proceed along a similar patho-
genetic pathway. Second, the APC mutational spectrum is sub-
stantially different in RER tumors from that in non-RER tumors.
This observation provides additional evidence that genetic insta-
bility is not simply an epiphenomenon associated with tumori-
genesis, but has a direct, causal role in colorectal neoplasia.
Many previous observations indicate that mutational inactiva-
tion ofAPC plays a central role in colorectal tumorigenesis. Gene
carriers from familial adenomatous polyposis families and mice
with heritable mutations of APC develop numerous colorectal
and small intestinal tumors (38, 43-45). Truncation or complete
absence of APC protein can be demonstrated in the great
majority of colorectal tumors (38,40,42,46-48). Such mutations
can be detected in the smallest adenomas studied (40, 46-48) as
well as in dysplastic aberrant crypt foci, which appear to be the
very earliest histological manifestation of neoplasia (41, 49). In
light of the differences in genetic instability and other features
Table 3. Summary of APC mutations in RER and
non-RER tumors
Total no. of mutations
Point mutations
Transitions
C:G T:A
A:T - G:C
Transversions
C:G A:T
A:T T:A
G:C T:A
Frameshift mutations
Deletion
1 bp
2 bp
4 bp
8 bp
17 bp
Insertion
1 bp
4 bp
5 bp
Frameshifts at each target repeat
Mono-
(A)n
Mono- or di-
Tri-
Nonrepeat
RER
tumors
37
11(30%)
10
0
0
0
126 (70%)
11
7
0
0
0
8
0
0
19 (51%)
18 (49%)
21 (57%)
0
5 (14%)
Non-RER
tumors
64
34 (53%)
22
2
4
2
4
30 (47%)*
11
5
1
1
1
9
1
1
9 (14%)t
7 (11%)t
12 (19%)§
1
18 (28%)
characteristic of RER compared with non-RER tumors, it was
possible that the molecular pathogenesis of these two tumor types
differed considerably. Indeed, TGF-P receptor II mutations have
been identified exclusively in RER cases (24, 25). However, the
data presented here demonstrate that a critical and probably
initiating step in colorectal neQplasia, namelyAPC mutation, is
common to both tumor types. Data from other studies indicate
that ras and p53 mutations also occur in both tumor types (1, 3,
50), although larger studies will be needed to better quantify the
relative prevalence and spectra of these alterations. The clinical
and biological differences that exist between RER and non-RER
tumors may result from genetic alterations that occur exclusively
in RER cases, such as those demonstrated in the TGF-3 receptor
(24, 25), although host factors are also likely to play a part.
Genome-wide mutations at (A)n tracts are common in colo-
rectal cancers exhibiting a mutator phenotype (1), and the data
presented here demonstrate a direct link between such genetic
instability and cancer gene mutations. The reason why (A)n tract
mutations were more common than dinucleotide repeat alter-
ations likely involves the relative frequency of mononucleotide
and dinucleotide repeats withinAPC. For example, runs of three
or more (CA), (AT), (AG), or (TG) dinucleotide repeats occur
3, 2, 8, and 1 times, respectively, within the entire APC coding
sequence comparedwith 278 runs of (A).23, 103 runs of (A)u4 and
33 runs of (A)s5. The relatively high frequency of (A)n tracts
within the APC gene may in part explain the tumor spectrum
arising in HNPCC patients. We hypothesize that genes involved
in the initiation of tumors that are common in HNPCC, such as
colorectal and uterine cancers, may be prone to mutation because
of a higher frequency of microsatellites within their coding
sequence. Thus, the initiating role of inactivatingAPC mutations
in colorectal tumorigenesis and a corresponding relative abun-
dance of microsatellite sequences in the APC coding sequence
may be analogous to the situation in uterine cancer, for which the
initiating gene remains, as yet, uncharacterized. In contrast, such
microsatellites may be rare in genes involved in the initiation of
lung cancer, which is not part of the HNPCC tumor spectrum. A
lower frequency of (A)n tracts in the murine APC sequence may
also partly explain the absence of colon tumors in transgenic mice
with homozygous defects in mismatch repair genes (51, 52). Runs
of 3,4, and 5 (A)n repeats are 25%, 43%, and 32% more common,
respectively, in the human than in the murine APC sequence.
Interestingly, in TGF-(3 receptor II, the only other gene identified
so far as a specific target for mutation in RER tumors, the
microsatellite content differs considerably between the human
and mouse homologs. The (A)1o tract in the human sequence that
is mutated in 90% of RER colorectal tumors (24, 25) is com-
pletely absent from the mouse homolog.
The predominance of -1 or + 1 frameshifts in RER tumors
and the complete absence of deletions or insertions involving
more than 1 bp in tumors with mismatch repair gene mutations
indicates either that larger replication slippages do not occur
in the APC gene or that they are efficiently repaired by other
mechanisms. Indeed the only frameshift mutations of more
than 2 bp noted in this study were in non-RER tumors.
An excess of A:T transversions or -2 deletions has been
noted previously in the aprt gene in a clone of CHO cells with
a mutator phenotype and defective mismatch binding (8, 11),
but this was not apparent in RER tumors in this study.
However, observations in a variety of cell lines indicate that the
mutator phenotype is a heterogeneous phenomenon with
substantial variation between cell lines in both mutation rate
and in the type of mutation that arises (12, 13, 19, 53). Hence,
detailed analysis of a large series of primary tumors, such as
reported here, allows independent determination of the effect
of genetic instability on mutations in genes known to be
involved in tumorigenesis and is a robust method of assessing
its relevance in an in vivo human context.
Mismatch repair capacity is intact in normal tissues of most
HNPCC patients because of the presence of the relevant wild-
Summary data on the 101 APC gene mutations characterized by
sequencing, comparing the mutational spectrum and target sequences
in RER tumors with those in non-RER tumors.
*p < 0.04; tP < 0.0002; 1P < 0.00007; §P < 0.0003.
Genetics: Huang et al.
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type mismatch repair allele inherited from the unaffected parent.
At some stage during tumorigenesis, the wild-type allele is
inactivated, leading to mismatch repair deficiency in the tumor.
In sporadic RER cases, both alleles of a MMR gene are inacti-
vated somatically. It has not been clear when these mismatch
repair deficiencies appear. Genetic instability occurring in the late
stages of tumorigenesis, accelerating the rate of tumor progres-
sion, was a reasonable assumption. However, the substantial
differences in mutational spectra in RER and non-RER tumors
observed in this study now strongly suggest that MMR deficien-
cies precede APC mutations in the majority of cases. APC gene
alterations appear to be required for neoplastic transformation
and so our findings indicate that, in patients with RER tumors,
genetic instability leads to tumorigenesisviaAPC inactivation and
hence is indirectly responsible for both tumor initiation and later
progression. This hypothesis is compatible with some, but not all,
previous data. It is consistent with the observation that most
adenomas from HNPCC patients are MMR deficient (4), and
that microsatellite instability is demonstrable at an early stage in
some sporadic adenomas (53). However, the observation that
adenomas are not much more frequent in HNPCC cases than in
the general population (54, 55) would not necessarily have been
predicted on the basis of this hypothesis. Perhaps adenomas
progress so rapidly to carcinomas in HNPCC patients that
adenomas only appear to occur at lower frequency than expected
(55). Alternatively, a significant proportion of early adenomas
with MMR deficiency regress due to the host responses alluded
to above, leaving only those tumors capable of escaping such
responses. The latter adenomas would then rapidly progress to
malignancy due to a reduced capacity for DNA repair, manifest
as an elevated mutation rate. Further studies correlating inci-
dence of early colorectal lesions and genetic instability in HNPCC
patients may clarify this issue.
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